COMPANY

Endevica Bio

HQ: Northbrook, IL source · endevicabio.com ↗

Location: Northbrook, IL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Cancer Weight Loss Pancreatic Ductal Adenocarcinoma (mPDAC) Unresectable Pancreatic Ductal Adenocarcinoma Metastatic PDAC Cachexia TCMCB07 mifomelatide

3Trials (company is sponsor)

Timeline

Apr 28, 2025 Trial start Phase 2: Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy source ↗
Jul 12, 2022 Trial start Phase 1: A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Phase 2 · Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy · NCT06937177

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06937177	Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy	Phase 2	Recruiting	Apr 28, 2025	2027-10 (estimated)
NCT07399015	Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC	Not listed	No longer available	Not listed	Not listed
NCT05529849	A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects	Phase 1	Completed	Jul 12, 2022	Dec 12, 2022 (actual)